AXSOME DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Axsome Therapeutics, Inc. and Encourages

Katie R. Ochoa

NEW YORK–(Business WIRE)–#AXSM–Bragar Eagel & Squire, P.C., a nationally acknowledged stockholder legal rights legislation organization, reminds investors that a course motion lawsuit has been submitted from Axsome Therapeutics, Inc. (“Axsome” or the “Company”) (NASDAQ: AXSM) in the United States District Court docket for the Southern District of New York on behalf of all people and entities who purchased or or else obtained Axsome securities concerning December 30, 2019 and April 22, 2022, both equally dates inclusive (the “Class Period”). Buyers have until July 12, 2022 to implement to the Courtroom to be appointed as guide plaintiff in the lawsuit.

Click right here to take part in the motion.

Axsome is a biopharmaceutical firm that engages in the advancement of novel therapies for central anxious technique ailments in the United States. The Firm is developing, amongst other solution candidates, AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational drugs for the acute procedure of migraine.

Axsome constantly touted AXS-07’s regulatory and industrial potential customers in anticipation of the Company’s submission a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for AXS-07 for the acute cure of migraine (the “AXS-07 NDA”) based mostly on the drug’s constructive results in two Phase 3 trials. Having said that, unbeknownst to traders, the Company’s preparing and eventual submission of the AXS-07 NDA was plagued with chemistry, manufacturing, and manage (“CMC”) difficulties.

The criticism alleges that, through the Course Interval, Defendants manufactured materially fake and deceptive statements concerning the Company’s organization, functions, and potential clients. Specially, Defendants manufactured fake and/or misleading statements and/or failed to disclose that: (i) Axsome’s CMC techniques were deficient with respect to AXS-07 and its manufacturing procedure (ii) as a end result, Axsome was unlikely to post the AXS-07 NDA on its initially represented timeline (iii) the foregoing CMC concerns remained unresolved at the time that the Fda reviewed the AXS-07 NDA (iv) accordingly, the Fda was not likely to approve the AXS-07 NDA (v) as a result of all the foregoing, Axsome experienced overstated AXS-07’s regulatory and industrial prospective customers and (vi) as a final result, the Company’s community statements were being materially phony and misleading at all appropriate situations.

On November 5, 2020, Axsome issued a press release reporting the Company’s 3rd quarter 2020 outcomes. That push release disclosed that the Organization “plans to submit the [AXS-07] NDA to the Food and drug administration in the first quarter of 2021, as opposed to preceding steerage of the fourth quarter of 2020, to allow for inclusion of supplemental manufacturing information and facts to ensure a strong submission package deal.”

On this news, Axsome’s inventory rate fell $5.22 for every share, or 6.99%, to close at $69.51 for each share on November 5, 2020.

Then, on April 25, 2022, Axsome disclosed in a filing with the U.S. Securities and Exchange Fee that, “[o]n April 22, 2022, Axsome . . . was knowledgeable by the [FDA] that [CMC] difficulties recognized all through the FDA’s evaluate of the Company’s [NDA] for its AXS-07 product or service applicant for the acute procedure of migraine are unresolved.” That submitting also disclosed that “[b]ased on the time remaining in the NDA assessment cycle, the Business expects to acquire a Entire Response Letter [(‘CRL’)] with regard to this NDA on or about the Prescription Drug User Charge Act concentrate on motion day of April 30, 2022.”

On this news, Axsome’s stock value fell $8.60 for every share, or 21.99%, to close at $30.50 per share on April 25, 2022.

Last but not least, on May 2, 2022, Axsome declared that it received a CRL from the Fda relating to the AXS-07 NDA for the acute cure of migraine. In accordance to the Company, “[t]he principal factors specified in the CRL relate to [CMC] issues,” like “the want for further CMC knowledge pertaining to the drug product and producing procedure.”

If you ordered or usually obtained Axsome shares and suffered a reduction, are a lengthy-phrase stockholder, have info, would like to find out extra about these promises, or have any questions relating to this announcement or your legal rights or pursuits with regard to these matters, make sure you get in touch with Brandon Walker or Melissa Fortunato by e-mail at [email protected], telephone at (212) 355-4648, or by filling out this contact variety. There is no price tag or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally regarded legislation company with places of work in New York, California, and South Carolina. The organization represents specific and institutional traders in commercial, securities, spinoff, and other intricate litigation in point out and federal courts across the place. For more info about the organization, be sure to check out www.bespc.com. Legal professional marketing. Prior success do not ensure related results.

Contacts

Bragar Eagel & Squire, P.C.

Brandon Walker, Esq.

Melissa Fortunato, Esq.

(212) 355-4648

[email protected]
www.bespc.com

Next Post

Henry Kissinger reflects on leadership, global crises and the state of U.S. politics

Judy Woodruff: Between the war in Ukraine and tensions with China, President Biden’s handling of international coverage problems is becoming place to the test. In previous Secretary of Condition Henry Kissinger’s new e-book, “Management: Six Experiments in Environment Approach,” he examines how previous leaders in the era soon after the […]